Navigation Links
Beta-Blockers Should Not Be First Choice for High Blood Pressure

Beta-blocker drugs such as Tenormin, Inderal and Lopressor should not be a doctor’s first choice for treating high blood pressure//, according to a large new review of studies.

The review, coming on the heels of several similar large reviews, found that beta-blocker users have a slightly higher risk of death and cardiovascular disease than patients who use calcium channel blockers such as Norvasc and Cardizem to manage their blood pressure.

Patients who take diuretics such as hydrochlorothiazide or a group of drugs called RAS inhibitors (brand names include Altace, Lotensin, and Cozaar) have risks similar to those taking beta-blockers.

Dr. Charles Shey Wiysonge of the Ministry of Public Health in Cameroon, who led the new review, said many recent reviews “arrived at similar conclusions — that the available evidence does not support the use of beta-blockers as first-line drugs in the treatment of hypertension.”

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Wiysonge said the Cochrane review is different from other recent reviews because it compares beta-blockers head-to-head against specific antihypertensive medications, rather than comparing beta-blockers against all other high blood pressure medicines as a group.

After combing through 13 studies of 91,561 patients, Wiysonge and colleagues found no difference in the risk of death or cardiovascular disease among those who used beta-blockers, diuretics and RAS inhibitor drugs.

However, the absolute risk of death was a half-percent greater among beta-blocker users compared to those taking calcium channel blockers.

In addition, patients taking beta-blockers had a 1.3 percent increase in the risk of cardiovascular disease — mostly strokes — compared to those taking calcium channel blockers.

Also, “patients who used beta-blockers were more likely to experience undesirable effects and abandon their antihypertension medications” compared to patients who took diuretics or RAS inhibitors, Wiysonge said.

A review of 22 studies published in the medical journal The Lancet in January may suggest another reason to be wary of beta-blockers for high blood pressure. The review concluded that diuretics and beta-blocker treatments may increase the chances of developing type 2 diabetes.

Lancet author Dr. William Elliott of Rush University Medical Center in Chicago said antihypertensive drugs such as ACE inhibitors and angiotensin receptor blockers — types of RAS drugs — were associated with the lowest risk of developing diabetes.

Source-Newswie
SRM
'"/>




Related medicine news :

1. Beta-Blockers Should Be the Second Line of Treatment
2. Babies Should Get Vitamin D Supplement
3. How Much Should Athletes Drink?
4. Angioplasty Should be the Standard
5. Parents Should Look For Signs Of Children Becoming Overweight
6. Diabetics Should Adopt Better Preventive Measures
7. Before Weight Loss Surgery One Should Get Tested for Bacteria
8. Should we avoid energy drinks to protect our teeth?
9. Parents Should Beware of Violent Video Games
10. Exercises Should Be Recommended During Pregnancy
11. Khushboo Should ‘Talk about Safe Sex’ and not ‘ Premarital Sex’ Says Miniter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology: